



Final Appraisal Recommendation

Advice No: 1012 – May 2012

Fluorouracil/salicylic acid (Actikerall®) 0.5%/10% cutaneous solution

Limited submission by Almirall Ltd

Recommendation of AWMSG

Fluorouracil/salicylic acid (Actikerall®) is recommended as an option for use within NHS Wales for the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (grade I/II) in immunocompetent adult patients.

Additional note(s):

Fluorouracil/salicylic acid (Actikerall®) for the above indication met the following criteria for eligibility for a limited submission:

- Anticipated usage in NHS Wales is considered to be of minimal budgetary impact.
- Estimated small difference in cost compared to comparators.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report, the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion, lay perspective and discussions at AWMSG.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Almirall Ltd
Date of first issue	May 2012
Last reviewed	August 2016

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1012: Fluorouracil/salicylic acid (Actikerall®) 0.5%/10% cutaneous solution. May 2012.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.